SLC47A1

From Wikipedia, the free encyclopedia

Hypothetical protein FLJ10847

Identifiers

FLJ10847; MATE1; MATE2; MGC64822

External IDs

OMIM: 609832 MGI: 1914723 HomoloGene: 74693

Gene ontology
Molecular Function:	• drug transporter activity • antiporter activity
Cellular Component:	• membrane
Biological Process:	• multidrug transport

RNA expression pattern

More reference expression data

Orthologs

Human

Mouse

Refseq

NM_018242 (mRNA)
NP_060712 (protein)

NM_026183 (mRNA)
NP_080459 (protein)

Location

Chr 17: 19.38 - 19.42 Mb

Chr 11: 61.16 - 61.19 Mb

Pubmed search

[1]

[2]

Hypothetical protein FLJ10847, also known as FLJ10847, is a human gene.^[1]

This gene is located within the Smith-Magenis syndrome region on chromosome 17. It encodes a protein of unknown function.^[1]

[edit] References

^ ^a ^b Entrez Gene: FLJ10847 hypothetical protein FLJ10847.

[edit] Further reading

Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.". Gene 138 (1-2): 171-4. PMID 8125298.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library.". Gene 200 (1-2): 149-56. PMID 9373149.
Bi W, Yan J, Stankiewicz P, et al. (2002). "Genes in a refined Smith-Magenis syndrome critical deletion interval on chromosome 17p11.2 and the syntenic region of the mouse.". Genome Res. 12 (5): 713-28. doi:10.1101/gr.73702. PMID 11997338.
Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899-903. doi:10.1073/pnas.242603899. PMID 12477932.
Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs.". Nat. Genet. 36 (1): 40-5. doi:10.1038/ng1285. PMID 14702039.
Otsuka M, Matsumoto T, Morimoto R, et al. (2006). "A human transporter protein that mediates the final excretion step for toxic organic cations.". Proc. Natl. Acad. Sci. U.S.A. 102 (50): 17923-8. doi:10.1073/pnas.0506483102. PMID 16330770.
Ohta KY, Inoue K, Hayashi Y, Yuasa H (2006). "Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney.". Drug Metab. Dispos. 34 (11): 1868-74. doi:10.1124/dmd.106.010876. PMID 16928787.
Omote H, Hiasa M, Matsumoto T, et al. (2007). "The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations.". Trends Pharmacol. Sci. 27 (11): 587-93. doi:10.1016/j.tips.2006.09.001. PMID 16996621.
Tsuda M, Terada T, Asaka J, et al. (2007). "Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1.". Am. J. Physiol. Renal Physiol. 292 (2): F593-8. doi:10.1152/ajprenal.00312.2006. PMID 17047166.
Chen Y, Zhang S, Sorani M, Giacomini KM (2007). "Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family.". J. Pharmacol. Exp. Ther. 322 (2): 695-700. doi:10.1124/jpet.107.123554. PMID 17495125.
Tanihara Y, Masuda S, Sato T, et al. (2007). "Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.". Biochem. Pharmacol. 74 (2): 359-71. doi:10.1016/j.bcp.2007.04.010. PMID 17509534.
Kajiwara M, Terada T, Asaka J, et al. (2007). "Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1.". Am. J. Physiol. Renal Physiol. 293 (5): F1564-70. doi:10.1152/ajprenal.00322.2007. PMID 17855482.